GO
Loading...

Actavis Inc

More

  • *RenaissanceRe to buy Platinum for $1.9 bln. NEW YORK, Nov 24- U.S. stock index futures pointed to a higher open on Monday, indicating that major indexes would move further into record territory on the back of multiple merger deals and hopes that China will take further accommodative monetary policy action. Equities closed a fifth straight week of advances Friday,...

  • US STOCKS-Futures rise, boosted by merger activity Monday, 24 Nov 2014 | 8:14 AM ET

    *RenaissanceRe to buy Platinum for $1.9 bln. NEW YORK, Nov 24- U.S. stock index futures rose on Monday, indicating that major indexes would move further into record territory, on the back of multiple merger deals and hopes that China will take further accommodative monetary policy action. Equities closed a fifth straight week of advances Friday, with the Dow and S&P...

  • Goldman Sachs Group Inc retained its No. 1 position as M&A adviser with deals worth $877 billion, followed by JPMorgan Chase& Co with $651 billion and Citigroup Inc with $633 billion. The $66.4 billion bid for Allergan Inc by Actavis PLC this week more than doubled the total value of deals in the healthcare sector to $364 billion. Halliburton Co's plans to buy...

  • Valeant slashes stake in Allergan after losing bid Thursday, 20 Nov 2014 | 7:14 PM ET

    Nov 20- Valeant Pharmaceuticals International Inc said it cut its stake in Allergan Inc to 0.1 percent from 9.7 percent, three days after Actavis Plc trumped its offer for the Botox maker. Pershing Square Capital Management informed Valeant that PS Fund 1 sold all of its 2.2 million shares in Allergan allocated to Valeant USA, Valeant said in a regulatory filing.

  • Nov 20- Canada's Valeant Pharmaceuticals International Inc said it may buy back up to $2 billion worth of securities, replacing a previous $1.5 billion program under which it bought back no securities. The announcement comes a few days after acquisition-hungry Valeant's $54 billion offer to buy Botox maker Allergan Inc was trumped by Actavis Plc's $66...

  • *Nikkei erases gains, Asia shares hit by weak commodity prices. TOKYO, Nov 19- Japanese shares gave up early gains on Wednesday as investors booked profits after Prime Minister Shinzo Abe delayed a tax hike and said he would call a snap election to seek a fresh mandate for his economic policies. Japan's Nikkei erased earlier gains to stand flat by midday, showing...

  • TOKYO, Nov 19- Japanese stocks rose on Wednesday as investors held out hope for more robust growth after Prime Minister Shinzo Abe delayed a tax hike and called an early election to seek a fresh mandate for his aggressive policies to shore up the economy. MSCI's broadest index of Asia-Pacific shares outside Japan was a touch lower while Japan's Nikkei rose 0.6...

  • Actavis Plc, Gilead Sciences and other biotechs were among the biggest drivers, a day after Allergan agreed to be bought by Actavis. Shares of Actavis were up 8.7 percent at $269.60, helped by bullish analyst notes, while Gilead's stock rose 3.3 percent to $103.71 percent. "A little bit of a risk trade is coming back on, and those are the areas for the M&A," said Uri...

  • Actavis Plc, Gilead Sciences, Celgene and other biotech names were among the S&P 500' s biggest drivers, a day after Allergan agreed to be bought by Actavis. The S&P health care index was up 1.6 percent, while shares of Actavis were up 8.3 percent, Gilead's rose 3.3 percent and shares of Celgene were up 2.4 percent. Helping Actavis were bullish analyst notes.

  • US STOCKS-S&P 500 hits record, healthcare leads gains Tuesday, 18 Nov 2014 | 1:45 PM ET

    Actavis Plc, Gilead, Celgene and other biotech names were among the S&P 500' s biggest drivers, a day after Allergan agreed to be bought by Actavis. The S&P health care index was up 1.4 percent, while shares of Actavis were up 7.7 percent, Gilead's rose 2.9 percent and shares of Celgene were up 2.4 percent. Helping Actavis were bullish analyst notes.

  • US STOCKS-S&P 500 hits record again; Actavis rallies Tuesday, 18 Nov 2014 | 11:01 AM ET

    NEW YORK, Nov 18- U.S. stocks rose on Tuesday, lifting the S&P 500 to a record high, boosted by healthcare after Actavis' acquisition of Allergan triggered bullish analyst notes. Allergan on Monday accepted a $66 billion takeover bid from Actavis Plc in cash and stock. At least two analysts raised Actavis' price target, one to as high as $300.

  • Ackman has the luck of a loser, to the tune of $2.2B Tuesday, 18 Nov 2014 | 7:02 AM ET
    Bill Ackman

    Heads he wins. Tails he wins. That was the situation Bill Ackman found himself in — or perhaps more accurately, orchestrated — on Monday.

  • Mega-mergers are popular again on Wall Street Tuesday, 18 Nov 2014 | 6:47 AM ET

    Deals worth $100 billion on Monday put the Street on pace for a year rivaling the dot-com bubble era and the private equity surge just before the financial crisis.

  • A day after shock data showing Japan slipping into recession had rattled financial markets, Japan's Nikkei rose 1.7 percent, erasing about a half of Monday's 3.0 percent fall. Prime Minister Shinzo Abe is expected to announce later in the day that he is calling a snap election, banking on the ruling Liberal Democrat Party trouncing a weak opposition to reaffirm...

  • *Baker Hughes rallies, Halliburton tumbles after deal. Shares of Baker Hughes, up 8.9 percent, and Allergan, up 5.3 percent, gave the S&P 500 its biggest boost after Halliburton said it would buy Baker Hughes and Allergan agreed to be bought by Actavis. "It shows the strength of the overall market that you could have this recession news out of Japan, and yet have the...

  • Nov 17- Botox maker Allergan Inc on Monday accepted a $66 billion takeover bid from Actavis Plc, ending a seven-month hostile pursuit by activist investor William Ackman and Valeant Pharmaceuticals International Inc.. Besides the higher price tag, the Actavis deal came with only $400 million in R&D cuts for Allergan, far less than the $900 million decrease...

  • *Brent falls toward $78 as Japanese growth stalls. NEW YORK, Nov 17- Oil prices fell and global equity markets were mixed on Monday after news that Japan unexpectedly slipped into recession in the third quarter renewed concerns about the world economy, but merger activity and comment about European stimulus capped declines. Brent oil initially fell more than $1...

  • *Baker Hughes rallies, Halliburton tumbles after deal. Shares of Baker Hughes, up 10.2 percent, and Allergan, up 5.1 percent, led gains on the S&P 500 after Halliburton said it would buy Baker Hughes and Allergan agreed to be bought by Actavis. The largest percentage gainer on the S&P 500 was Baker Hughes, while the largest decliner was Halliburton, down 10.1 percent.

  • NEW YORK, Nov 17- Actavis will issue around US $27.5 bn of new debt to finance its US $66 bn acquisition of Botox-maker Allergan, but about half of it will be short-dated to help the company keep its investment-grade ratings. Both Moody's and Fitch said they would not downgrade Actavis to junk despite the increased debt, believing strong cash flow will enable it to...

  • Losing Allergan deals blow to Valeant reputation Monday, 17 Nov 2014 | 1:25 PM ET

    WINNIPEG/ NEW YORK Nov 17- The failure of Valeant Pharmaceuticals International Inc to buy Allergan Inc leaves it with nothing to show for a seven-month, bruising pursuit. Losing Allergan to Actavis PLC also hurts Valeant's deal-making reputation, said a source close to the company not authorized to speak publicly. Allergan's rebuff will embolden future...